Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204122798> ?p ?o ?g. }
- W3204122798 endingPage "4820" @default.
- W3204122798 startingPage "4820" @default.
- W3204122798 abstract "Resistance to targeted therapies is a complex and multifactorial process that culminates in the selection of a cancer clone with the ability to evade treatment. Chronic myeloid leukemia (CML) was the first malignancy recognized to be associated with a genetic alteration, the t(9;22)(q34;q11). This translocation originates the BCR-ABL1 fusion gene, encoding the cytoplasmic chimeric BCR-ABL1 protein that displays an abnormally high tyrosine kinase activity. Although the vast majority of patients with CML respond to Imatinib, a tyrosine kinase inhibitor (TKI), resistance might occur either de novo or during treatment. In CML, the TKI resistance mechanisms are usually subdivided into BCR-ABL1-dependent and independent mechanisms. Furthermore, patients' compliance/adherence to therapy is critical to CML management. Techniques with enhanced sensitivity like NGS and dPCR, the use of artificial intelligence (AI) techniques, and the development of mathematical modeling and computational prediction methods could reveal the underlying mechanisms of drug resistance and facilitate the design of more effective treatment strategies for improving drug efficacy in CML patients. Here we review the molecular mechanisms and other factors involved in resistance to TKIs in CML and the new methodologies to access these mechanisms, and the therapeutic approaches to circumvent TKI resistance." @default.
- W3204122798 created "2021-10-11" @default.
- W3204122798 creator A5016566105 @default.
- W3204122798 creator A5029407987 @default.
- W3204122798 creator A5030157549 @default.
- W3204122798 creator A5032971294 @default.
- W3204122798 creator A5038570947 @default.
- W3204122798 creator A5052287429 @default.
- W3204122798 creator A5090598948 @default.
- W3204122798 date "2021-09-26" @default.
- W3204122798 modified "2023-10-01" @default.
- W3204122798 title "Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance" @default.
- W3204122798 cites W1195042279 @default.
- W3204122798 cites W1483167997 @default.
- W3204122798 cites W1490418776 @default.
- W3204122798 cites W1508385597 @default.
- W3204122798 cites W1528621722 @default.
- W3204122798 cites W1546346721 @default.
- W3204122798 cites W1554671812 @default.
- W3204122798 cites W1600365609 @default.
- W3204122798 cites W1606656369 @default.
- W3204122798 cites W1678762333 @default.
- W3204122798 cites W1840691103 @default.
- W3204122798 cites W1901398265 @default.
- W3204122798 cites W1913762249 @default.
- W3204122798 cites W1935318206 @default.
- W3204122798 cites W1946154114 @default.
- W3204122798 cites W1964023655 @default.
- W3204122798 cites W1964280661 @default.
- W3204122798 cites W1964614068 @default.
- W3204122798 cites W1965260090 @default.
- W3204122798 cites W1965570423 @default.
- W3204122798 cites W1965627667 @default.
- W3204122798 cites W1966006461 @default.
- W3204122798 cites W1966814962 @default.
- W3204122798 cites W1967174976 @default.
- W3204122798 cites W1968108412 @default.
- W3204122798 cites W1968747503 @default.
- W3204122798 cites W1969189095 @default.
- W3204122798 cites W1969628021 @default.
- W3204122798 cites W1972180057 @default.
- W3204122798 cites W1973720500 @default.
- W3204122798 cites W1973899902 @default.
- W3204122798 cites W1977508777 @default.
- W3204122798 cites W1978721974 @default.
- W3204122798 cites W1980127792 @default.
- W3204122798 cites W1981475784 @default.
- W3204122798 cites W1982035148 @default.
- W3204122798 cites W1982401508 @default.
- W3204122798 cites W1985054311 @default.
- W3204122798 cites W1986995673 @default.
- W3204122798 cites W1987152779 @default.
- W3204122798 cites W1987180287 @default.
- W3204122798 cites W1987349202 @default.
- W3204122798 cites W1987699496 @default.
- W3204122798 cites W1990915902 @default.
- W3204122798 cites W1991692801 @default.
- W3204122798 cites W1994041743 @default.
- W3204122798 cites W1994400524 @default.
- W3204122798 cites W1997561098 @default.
- W3204122798 cites W1999614615 @default.
- W3204122798 cites W2000157636 @default.
- W3204122798 cites W2001535881 @default.
- W3204122798 cites W2001590374 @default.
- W3204122798 cites W2004688948 @default.
- W3204122798 cites W2007190305 @default.
- W3204122798 cites W2009803958 @default.
- W3204122798 cites W2013225336 @default.
- W3204122798 cites W2013477475 @default.
- W3204122798 cites W2016809033 @default.
- W3204122798 cites W2022182608 @default.
- W3204122798 cites W2024021544 @default.
- W3204122798 cites W2024290860 @default.
- W3204122798 cites W2025329130 @default.
- W3204122798 cites W2028178274 @default.
- W3204122798 cites W2028459384 @default.
- W3204122798 cites W2030430614 @default.
- W3204122798 cites W2031585970 @default.
- W3204122798 cites W2031892240 @default.
- W3204122798 cites W2033288780 @default.
- W3204122798 cites W2033661259 @default.
- W3204122798 cites W2033989981 @default.
- W3204122798 cites W2034892057 @default.
- W3204122798 cites W2036656143 @default.
- W3204122798 cites W2038906686 @default.
- W3204122798 cites W2039045990 @default.
- W3204122798 cites W2047224624 @default.
- W3204122798 cites W2047632409 @default.
- W3204122798 cites W2048071930 @default.
- W3204122798 cites W2048809946 @default.
- W3204122798 cites W2049228075 @default.
- W3204122798 cites W2054882807 @default.
- W3204122798 cites W2056278417 @default.
- W3204122798 cites W2057206328 @default.
- W3204122798 cites W2058839737 @default.
- W3204122798 cites W2060996760 @default.
- W3204122798 cites W2061020520 @default.
- W3204122798 cites W2061493553 @default.